Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of Cardiovascular Development and Disease|April 25, 2025
Cerebral and Spinal Cord Protection Strategies in Aortic Arch SurgeryAndrea Myers, Ciprian Nita, Guillermo Martinez
The Journal of Pediatrics|January 15, 2010
Acceptability and practicality of musculoskeletal examination in acute general pediatric assessmentIain Goff, Belinda Bateman, Andrea Myers, et al.
The Journal of Pediatrics|October 1, 2008
Doctors likely to encounter children with musculoskeletal complaints have low confidence in their clinical skillsSharmila Jandial, Andrea Myers, Elspeth Wise, et al.
Clinical and Translational Science|May 27, 2022
Model-based dose selection to inform translational clinical oncology development of WNT974, a first-in-class Porcupine inhibitorYan Ji, Pai-Hsi Huang, Steve Woolfenden, et al.
JHLT Open|June 15, 2026
Complementary medicine as a holistic approach for pain management in heart and lung transplantationJacinta Nalpon, Julien Fessler, Andrea Myers, et al.
Arthritis and Rheumatism|March 13, 2003
Outcome in adults with juvenile idiopathic arthritis: a quality of life studyHelen E Foster, Nicola Marshall, Andrea Myers, et al.
International Journal of Laboratory Hematology|April 30, 2026
Point-Of-Care Testing of Fibrinogen by the qLab FIB System in Patients Taking Direct Oral Anticoagulants (DOACs)Christopher Long, Stephen MacDonald, Andrea Myers, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 21, 2022
Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatmentMélanie Wilbaux, David Demanse, Yi Gu, et al.
Clinical Pharmacology and Therapeutics|September 22, 2022
Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401)Mélanie Wilbaux, Shu Yang, Astrid Jullion, et al.
Arthritis Care & Research|April 5, 2016
Being as Normal as Possible: How Young People Ages 16-25 Years Evaluate the Risks and Benefits of Treatment for Inflammatory ArthritisRuth I Hart, Janet E McDonagh, Ben Thompson, et al.
Pageof 2